Mabwell(SH:688062) 中国基金报·2025-09-01 05:04Market Overview - On September 1, the A-share market experienced fluctuations, with the Shanghai Composite Index rising by 0.12%, the Shenzhen Component Index by 0.11%, and the ChiNext Index by 0.55% [1][2] - The total market turnover for the morning session was 1.85 trillion yuan, showing a slight decrease compared to the previous day, with over 3,100 stocks rising [2] Precious Metals Sector - The precious metals sector saw significant gains, with stocks related to gold, jewelry, cobalt, and minor metals becoming active [7] - Notable stocks such as Haixing Co., Jintong Co., and Shengda Resources reached their daily limit up, while Hunan Gold and Luoyang Molybdenum also saw increases [7] - The recent rise in international gold prices was attributed to the expectation of a Federal Reserve rate cut, which enhanced the appeal of precious metals as safe-haven assets amid geopolitical risks and trade tensions [8][9] Innovative Pharmaceuticals Sector - The pharmaceutical and biotechnology sector, particularly innovative drugs and CROs, showed strong performance, with stocks like Maiwei Biotech hitting the daily limit up [11][12] - Maiwei Biotech announced the approval of its two biosimilar products in Pakistan, marking a significant milestone for the company [16] - The recent adjustments to the national medical insurance catalog are expected to increase the value of innovative drugs, with a focus on new drugs and CAR-T products [17] Notable Stock Performances - In the precious metals sector, stocks such as Haixing Co. and Jintong Co. saw increases of around 10% [8] - In the innovative pharmaceuticals sector, Maiwei Biotech's stock rose by 20% to 57.60 yuan, with a trading volume of 24.39 million shares [13][14]